文献速递基础与转化研究临床试验与 GCP

慢病毒造血干细胞基因治疗早发型异染性脑白质营养不良:非随机开放标签1/2期试验及扩展可及性的长期结果

Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.
PubMed 文献 · Lancet · 2022-01-01

该研究整合分析了一项前瞻性非随机1/2期临床试验及扩展可及框架,29例症状前或早期症状的早发型异染性脑白质营养不良(MLD)患儿接受atidarsagene autotemcel(arsa-cel)治疗,与31例年龄和疾病亚型匹配的未治疗自然史队列比较。治疗后2年,晚婴型患者PBMC中ARSA活性较基线平均升高18.7倍(95%CI 8.3-42.2;p<0.0001),早期青少年型升高5.7倍(2.6-12.4;p<0.0001);粗大运动功能量表总分平均差异在晚婴型为66%(48.9-82.3),早期青少年型为42%(12.3-71.8),均显著。

要点

  • arsa-cel治疗后2年,晚婴型MLD患者PBMC中ARSA活性较基线平均升高18.7倍,早期青少年型升高5.7倍。
  • 与匹配的自然史队列相比,治疗后2年粗大运动功能量表总分平均差异晚婴型为66%,早期青少年型为42%。
  • 多数患者获得运动技能或稳定运动功能,认知发育正常,脱髓鞘和脑萎缩得到预防或延迟,症状前治疗获益更明显。

核心结论

  • arsa-cel治疗早发型MLD患儿可产生持续且有临床意义的获益,多数患者认知功能和运动发育得以保留,并减缓脱髓鞘和脑萎缩。

研究设计与样本

  • 研究为前瞻性非随机1/2期临床试验及扩展可及框架的整合分析,29例经生化和分子确诊的症状前或早期症状早发型MLD患儿接受arsa-cel治疗。
  • 对照组为31例年龄和疾病亚型匹配的未治疗早发型MLD自然史队列。
  • 患者在意大利米兰Ospedale San Raffaele接受治疗和随访;试验注册号NCT01560182。

主要发现

  • 至分析时,26例接受arsa-cel治疗的患者存活,中位随访3.16年(范围0.64-7.51)。
  • 2例患者死于疾病进展,1例死于突然事件,该事件被认为不太可能与治疗相关。
  • 经白消安预处理后,所有接受arsa-cel治疗的患者均显示基因修饰HSPC的持续多系植入。
  • 治疗后2年,PBMC中ARSA活性较基线显著升高:晚婴型平均升高18.7倍(95%CI 8.3-42.2;p<0.0001),早期青少年型平均升高5.7倍(95%CI 2.6-12.4;p<0.0001)。
  • 治疗后2年,粗大运动功能量表总分平均差异在晚婴型MLD患者为66%(95%CI 48.9-82.3),在早期青少年型MLD患者为42%(95%CI 12.3-71.8),与年龄和疾病亚型匹配的自然史患者相比均显著。

关键数值与推荐

  • 共同主要疗效终点:治疗患者与对照相比,治疗后2年粗大运动功能量表总分改善超过10%;以及治疗患者治疗后2年PBMC中ARSA活性较基线变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective treatment for metachromatic leukodystrophy (MLD) remains a substantial unmet medical need. In this study we investigated the safety and efficacy of atidarsagene autotemcel (arsa-cel) in patients with MLD. METHODS: This study is an integrated analysis of results from a prospective, non-randomised, phase 1/2 clinical study and expanded-access frameworks. 29 paediatric patients with pre-symptomatic or early-symptomatic early-onset MLD with biochemical and molecular confirmation of diagnosis were treated with arsa-cel, a gene therapy containing an autologous haematopoietic stem and progenitor cell (HSPC) population transduced ex vivo with a lentiviral vector encoding human arylsulfatase A (ARSA) cDNA, and compared with an untreated natural history (NHx) cohort of 31 patients with early-onset MLD, matched by age and disease subtype. Patients were treated and followed up at Ospedale San Raffaele, Milan, Italy. The coprimary efficacy endpoints were an improvement of more than 10% in total gross motor function measure score at 2 years after treatment in treated patients compared with controls, and change from baseline of total peripheral blood mononuclear cell (PBMC) ARSA activity at 2 years after treatment compared with values before treatment. This phase 1/2 study is registered with ClinicalTrials.gov, NCT01560182. FINDINGS: At the time of analyses, 26 patients treated with arsa-cel were alive with median follow-up of 3·16 years (range 0·64-7·51). Two patients died due to disease progression and one due to a sudden event deemed unlikely to be related to treatment. After busulfan conditioning, all arsa-cel treated patients showed sustained multilineage engraftment of genetically modified HSPCs. ARSA activity in PBMCs was significantly increased above baseline 2 years after treatment by a mean 18·7-fold (95% CI 8·3-42·2; p<0·0001) in patients with the late-infantile variant and 5·7-fold (2·6-12·4; p<0·0001) in patients with the early-juvenile variant. Mean differences in total scores for gross motor function measure between treated patients and age-matched and disease subtype-matched NHx patients 2 years after treatment were significant for both patients with late-infantile MLD (66% [95% CI 48·9-82·3]) and early-juvenile MLD (42% [12·3-71·8]). Most treated patients progressively acquired motor skills within the predicted range of healthy children or had stabilised motor performance (maintaining the ability to walk). Further, most displayed normal cognitive development and prevention or delay of central and peripheral demyelination and brain atrophy throughout follow-up; treatment benefits were particularly apparent in patients treated before symptom onset. The infusion was well tolerated and there was no evidence of abnormal clonal proliferation or replication-competent lentivirus. All patients had at least one grade 3 or higher adverse event; most were related to conditioning or to background disease. The only adverse event related to arsa-cel was the transient development of anti-ARSA antibodies in four patients, which did not affect clinical outcomes. INTERPRETATION: Treatment with arsa-cel resulted in sustained, clinically relevant benefits in children with early-onset MLD by preserving cognitive function and motor development in most patients, and slowing demyelination and brain atrophy. FUNDING: Orchard Therapeutics, Fondazione Telethon, and GlaxoSmithKline.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022. PMID: 35065785. doi:10.1016/S0140-6736(21)02017-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。